Global Macular Degeneration Treatment Market to Reach US$ 15.4 Billion by 2032, Impelled by Rising Incidences of Retinal Disorders

June 22, 2022 | Healthcare

The latest report by IMARC Group, titled “Macular Degeneration Treatment Market Report by Type (Dry Age-related Macular Degeneration, Wet Age-related Macular Degeneration), Stage of Disease (Early Stage, Intermediate Stage, Late Stage), Route of Administration (Intravenous Route, Intravitreal Route), End User (Hospitals, Ambulatory Surgical Center, and Others), and Region 2024-2032,” finds that the global macular degeneration treatment market size reached US$ 9.4 Billion in 2023. Macular degeneration is a neurodegenerative eye disorder caused by deterioration of the macula, the part of the retina that controls sharp, straight-ahead vision. It leads to blurred or complete vision loss in the center of the visual field. The condition is generally characterized by blind or blurry spots in the field of vision, visual distortions, and the inability to see in low light conditions. It can be treated by various therapeutic techniques, such as anti-angiogenic drugs, photodynamic laser therapies, contact lenses, and transitional lenses. In recent years, macular degeneration treatment has gained immense traction across the globe as timely treatment can help improve vision and reduce the risks of developing chronic or permanent blindness. 

Global Macular Degeneration Treatment Market Trends:

The rising incidences of retinal disorders and the surging awareness regarding available treatment options among the masses represent the primary factors driving the market growth. Besides this, since macular degeneration usually affects older adults, the expanding geriatric population is another major growth-inducing factor. Additionally, there has been a widespread prevalence of obesity and cardiovascular diseases (CVDs) due to sedentary lifestyles, changing dietary patterns, and unhealthy habits like smoking. In line with this, prolonged screen time owing to the growing usage of smartphones, laptops, and television is contributing to the development of eye conditions, which has augmented the demand for macular degeneration treatment. Furthermore, the leading players are extensively investing in research and development (R&D) activities to develop innovative and effective drugs. Along with this, the introduction of retinal gene therapies that involve injecting adeno-associated virus (AAV) into the body to prevent the growth of abnormal blood vessels has propelled the market growth. Other factors, including the rising popularity of biosimilars, increasing approvals of novel drugs, favorable government initiatives, improving healthcare infrastructure, and technological advancements, are also providing a positive thrust to the market growth. Looking forward, IMARC Group expects the market value to reach US$ 15.4 Billion by 2032, growing at a CAGR of 5.5% during the forecast period (2024-2032).

Market Summary:

  • Based on the type, the market has been bifurcated into dry and wet age-related macular degeneration. 
  • The market has been segregated based on the stage of disease into early, intermediate, and late stages. 
  • On the basis of the route of administration, the market has been classified as intravenous and intravitreal routes. 
  • Based on the end user, the market has been divided into hospitals, ambulatory surgical center, and others. 
  • Region-wise, the market has been segmented into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa. 
  • The competitive landscape of the market has also been examined, with some of the key players being Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, PanOptica, Inc., Pfizer Inc., Phio Pharmaceuticals Corp., Regeneron Pharmaceuticals Inc., Regenxbio Inc., and Santen Pharmaceutical Co. Ltd.


Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units US$ Billion
Segment Coverage Type, Stage of Disease, Route of Administration, End User, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, Panoptica, Pfizer Inc., Phio Pharmaceuticals, Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Santen Pharmaceutical Co. Ltd.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 3899
Five User License: US$ 4899
Corporate License: US$ 5899
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Website: https://www.imarcgroup.com/
Email: sales@imarcgroup.com
Americas: +1 631 791 1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Macular Degeneration Treatment Market to Reach US$ 15.4 Billion by 2032, Impelled by Rising Incidences of Retinal Disorders
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More